The most frequently reported side effects in Phase 2 trials are gastrointestinal: nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation
A few human studies support this effect, too, though more research on plaque reduction is required to confirm this benefit
Grand challenges in pharmaceutical research series: ridding the cold chain for biologics
Bifidobacterium strains that support digestion, nutrient absorption, and immunity
3 mg/kg) or vehicle respectively (combined with acute PVN injections of Bicuculline Methiodide 3 min prior to CNO administration when stated)
To view a copy of this licence, visit About this article Cite this article Hankir, M.K., Lutz, T.A